We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+3.15%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.57B
AUM Growth
+$120M
Cap. Flow
+$109M
Cap. Flow %
6.95%
Top 10 Hldgs %
44.48%
Holding
133
New
28
Increased
33
Reduced
33
Closed
26

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40.1M
2
CLDX icon
Celldex Therapeutics
CLDX
+$25.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.7M
4
HQY icon
HealthEquity
HQY
+$12.8M
5
ARKK icon
ARK Innovation ETF
ARKK
+$9.18M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$60.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$27.8M
3
CTLT
CATALENT, INC.
CTLT
+$24.5M
4
LH icon
Labcorp
LH
+$23.9M
5
MASI
Masimo
MASI
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 72.04%
2 Industrials 1.19%
3 Technology 0.06%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDA icon
101
Sonida Senior Living
SNDA
$1.97B
$433K 0.03%
+15,209
New +$462K
MREO
102
Mereo BioPharma
MREO
$45.9M
$415K 0.03%
259,470
-640,099
-71% -$1.28M
BKD icon
103
Brookdale Senior Living
BKD
$3.62B
$408K 0.03%
+79,146
New +$494K
JYNT icon
104
PUT
The Joint Corp
JYNT
$119M
$361K 0.02%
+5,500
New +$444K
FSTX
105
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$251K 0.02%
49,933
– –
MNKD icon
106
CALL
MannKind Corp
MNKD
$1.28B
$219K 0.01%
+50,000
New +$231K
CBIO
107
Crescent Biopharma
CBIO
$602M
$144K 0.01%
+1,000
New +$181K
AKYA
108
DELISTED
Akoya BioSciences
AKYA
– –
-91,568
Closed -$1.28M
AMN icon
109
AMN Healthcare
AMN
$1.28B
– –
-10,000
Closed -$1.15M
APLS
110
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-126,400
Closed -$4.17M
BMY icon
111
Bristol-Myers Squibb
BMY
$127B
– –
-464,801
Closed -$27.8M
CCRN
112
DELISTED
Cross Country Healthcare
CCRN
– –
-20,000
Closed -$425K
DNTH icon
113
Dianthus Therapeutics
DNTH
$5.68B
– –
-12,430
Closed -$1.45M
EDIT icon
114
CALL
Editas Medicine
EDIT
$399M
– –
-90,000
Closed -$3.7M
EDIT icon
115
PUT
Editas Medicine
EDIT
$399M
– –
-50,000
Closed -$2.05M
EVH icon
116
Evolent Health
EVH
$475M
– –
-100,170
Closed -$3.11M
FBRX icon
117
PUT
Forte Biosciences
FBRX
$1.12B
– –
-2,828
Closed -$210K
GOCO
118
DELISTED
GoHealth
GOCO
– –
-84,115
Closed -$6.35M
HSTM icon
119
HealthStream
HSTM
$793M
– –
-77,812
Closed -$2.22M
KRRO icon
120
Korro Bio
KRRO
$153M
– –
-600
Closed -$212K
KRRO icon
121
PUT
Korro Bio
KRRO
$153M
– –
-1,358
Closed -$479K
MASI
122
DELISTED
Masimo
MASI
– –
-67,000
Closed -$18.1M
NVAX icon
123
CALL
Novavax
NVAX
$1.23B
– –
-10,000
Closed -$2.07M
OM icon
124
Outset Medical
OM
$74.9M
– –
-3,167
Closed -$2.35M
SPY icon
125
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
– –
-100,000
Closed -$42.9M
2 3 4
5
6

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Eversept Partners held 133 positions worth $1.57B, up 8.3% from $1.45B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Eversept Partners deployed $109M of net new capital in Q4 2021, opening 28 new positions and adding to 33 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 80% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Labcorp, an estimated $23.9M trimmed.

  • Eversept Partners's largest Q4 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, an estimated $21.7M increase.
  • Eversept Partners's biggest Q4 2021 reduction was Labcorp, cutting an estimated $23.9M.
  • Eversept Partners fully exited Acceleron Pharma in Q4 2021, selling an estimated $60.1M.
  • Eversept Partners's ten largest holdings make up 44% of its $1.57B portfolio in Q4 2021.
  • Eversept Partners opened 28 new positions and closed 26 in Q4 2021.
  • Eversept Partners's portfolio value rose 8.3% quarter-over-quarter to $1.57B.

Based on Eversept Partners's 13F filing for Q4 2021, filed 14 Feb 2022.